Doxepin vs Trenbolone
FDA Approved vs Moderate Research
avoid Mechanism-based · 60% Both Doxepin and Trenbolone carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Doxepin Trenbolone
Weight 279.38 Da 270.37 Da (base)
Half-life ~15 hours ~3 days (acetate)
Type Tricyclic dibenzoxepin derivative (C19H21NO) 19-nortestosterone derivative (C18H22O2), trienone steroid
Key Benefits
Doxepin
01 FDA-approved specifically for sleep maintenance insomnia at ultra-low doses (3-6 mg as Silenor)
02 Highly selective H1 antihistamine at low doses, avoiding the side effects of traditional tricyclic antidepressants
03 Non-habit-forming with no dependence, tolerance, or abuse potential
04 No rebound insomnia upon discontinuation, unlike benzodiazepines and Z-drugs
05 Particularly effective for maintaining sleep in the latter half of the night, when many other sleep aids have worn off
06 Extremely well-tolerated side effect profile at ultra-low doses
Trenbolone
01 Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
02 Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
03 Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
04 Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
05 Significant increases in strength across all compound movements, often rapid in onset
06 Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
07 Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
08 Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Dosing Protocols
Doxepin
3-6 mg at bedtime (sleep) / Once daily at bedtime
Trenbolone
200-400 mg/week / Every other day (acetate) or 2x per week (enanthate)
Recomposition - Moderate (Acetate) 200-300 mg/week (50-75 mg every other day) Every other day
Advanced Cutting (Acetate) 300-400 mg/week (75-100 mg every other day) Every other day
Lean Bulk (Enanthate) 200-400 mg/week 2x per week
Contest Preparation - Advanced 300-500 mg/week Every other day (acetate) or 2x per week (enanthate)
Side Effects
Doxepin
Morning drowsiness or grogginess (more common at the 6 mg dose; uncommon at 3 mg)
Dry mouth (mild at ultra-low doses, much less than at antidepressant doses)
Nausea
Upper respiratory tract infection (observed in clinical trials at rates similar to placebo)
Trenbolone
Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
Night sweats, often drenching, requiring sheet changes
Significantly reduced cardiovascular endurance and aerobic capacity
Increased aggression, irritability, and shortened temper
Anxiety and restlessness, particularly at higher doses
Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
Elevated body temperature and increased sweating throughout the day
Acne and oily skin, particularly on shoulders, back, and chest
Accelerated hair loss in those genetically predisposed to male pattern baldness
Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
Increased heart rate and elevated blood pressure
Contraindications
Known hypersensitivity to doxepin or other dibenzoxepines
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
Untreated narrow-angle glaucoma
Severe urinary retention
Severe hepatic impairment (doxepin is extensively hepatically metabolized)
First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
Liver disease or significantly elevated liver enzymes
Kidney disease or impaired renal function
Uncontrolled hypertension
Polycythemia (hematocrit above 54% at baseline)
Prostate cancer or history of hormone-sensitive cancers
Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Research Evidence
Doxepin Trenbolone
Status FDA Approved Moderate Research
References 4 studies 5 studies
Latest — January 2023
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.